Investors
The Radiopharmaceutical industry leader in Korea
A fast growing biotech company with proven records
DuChemBio Strategies
Competitive advantages by "Choice and Concentration Strategy" tailored to the corporate development stages
Unlike other conventional biotech companies, DuChemBio has achieved a consolidated growth based on solid sales.
After securing cutting-edge manufacturing facilities and competent human resources,
DuChemBio has completed its own peculiar business scheme. It is expected to realize high profit from 2022.
※ Launching schedules for new drugs
-
F-DOPA
2019.12 -
FACBC
First half of 2022 -
FES
Second half of 2022 -
68Ga-PSMA-11
First half of 2023
Contact support@duchembio.com to get more information
